

Study or Subgroup	Events	Total (Weight (common) (Weight random) I	Proportion [95% CI]	Total Cardiac Adverse Drug Reactions
Irug = Osimertinib gawa,2021 Zhai,2021	2 2	43 40	0.1% 0.1%	1.5% 1.4%	0.05 [0.01; 0.16] 0.05 [0.01; 0.17]	1 : : : : : : : : : : : : : : : : : : :
Ли,2019 Teranishi,2022	4 2	94 61	0.3% 0.3%	1.6% 1.6%	0.04 [0.01; 0.11] 0.03 [0.00; 0.11]	
orenzi,2022 (ishikawa,2020	11 2	126 56	0.3% 0.2%	1.6% 1.5%	0.09 [0.04; 0.15] 0.04 [0.00; 0.12]	-
Kunimasa,2020 Kunimasa,2020 Kujiwara,2023 (40mg)	24 1	123 2	0.2 % 0.1% 0.0%	1.5% 1.5% 0.2%	0.04 [0.00, 0.12] 0.20 [0.13; 0.28] 0.50 [0.01; 0.99]	
ujiwara,2023 (4011g) ujiwara,2023 (80mg) ujiwara,2023 (80mg)	2	13 8	0.0% 0.0% 0.0%	0.2% 0.8% 0.4%	0.50 [0.01; 0.99] 0.15 [0.02; 0.45] 0.50 [0.16; 0.84]	
ujiwara,2023 (80mg)	2 2	8	0.0%	0.5%	0.25 [0.03; 0.65]	· · · · · · · · · · · · · · · · · · ·
ark,2020 CT02474355,2019	154	80 3014	0.4% 10.2%	1.6% 1.7%	0.03 [0.00; 0.09] 0.05 [0.04; 0.06]	<u>.</u>
ICT02094261,2015 falik,2022	13	210 60	0.6% 0.4%	1.6% 1.6%	0.06 [0.03; 0.10] 0.02 [0.00; 0.09]	 •
hao,2018 (40mg) hao,2018 (80mg)	1 1	15 16	0.0% 0.0%	1.0% 1.1%	0.07 [0.00; 0.32] 0.06 [0.00; 0.30]	1
iura,2018 gawa,2022	16 1	301 16	1.0% 0.0%	1.6% 1.1%	0.05 [0.03; 0.08] 0.06 [0.00; 0.30]	
rovencio,2021 lakao,2019	3 2	155 36	1.2% 0.1%	1.7% 1.4%	0.02 [0.00; 0.06] 0.06 [0.01; 0.19]	+
CT02157883,2015 /atanabe,2024	3 4	38 583	0.1% 12.6%	1.3% 1.7%	0.08 [0.02; 0.21]	<u>'</u>
ingh,2023	4	82 17	0.3% 0.0%	1.6% 1.1%	0.05 [0.01; 0.12]	1 1 1
hen,2024 hang,2023	1	202	4.6%	1.7%		1
ng,2023 014-000531-17,2024	1 18	110 210	1.4% 0.4%	1.7% 1.6%	0.09 [0.05; 0.13]	# <u></u>
ide,2020 ark,2024	15 1	199 73	0.5% 0.6%	1.6% 1.6%	0.08 [0.04; 0.12] 0.01 [0.00; 0.07]	 •
otal (common effect, 95% CI) otal (random effect, 95% CI)		5991	35.9%	40.8%	0.03 [0.02; 0.03] 0.05 [0.03; 0.06]	*
eterogeneity: Tau ² = 0.0008; Chi ²	= 166.38,	df = 29 ((P < 0.0001); I	² = 82.6%		
rug = Mefatinib /ang,2021 (60mg)	5	51	0.1%	1.4%	0.10 [0.03; 0.21]	
/ang,2021 (80mg) otal (common effect, 95% Cl)	6	55 106	0.1% 0.2%	1.4%	0.11 [0.04; 0.22] 0.10 [0.05; 0.16]	•
otal (random effect, 95% Cl) eterogeneity: Tau ² = 0; Chi ² = 0.0				2.8%	0.10 [0.05; 0.16]	
	J, uı = 1 (F	- v.oɔʾl	. ∪ _/ , ι – U 70			
rug = Afatinib 1,2022 CT02121250 2016	10	541	4.7%	1.7%	0.02 [0.01; 0.03]	<u> </u>
CT02131259,2016 CT02047903,2018	13 4	1602 152	31.6% 0.9%	1.7% 1.6%		<mark>-</mark> - -
009–014563–39,2013 akamura,2020	24 1	1154 30	9.2% 0.1%	1.7% 1.4%	0.03 [0.00; 0.17]	-
mit,2017 CT02044380,2016	2 2	13 14	0.0% 0.0%	0.8% 0.8%	0.15 [0.02; 0.45] 0.14 [0.02; 0.43]	
otal (common effect, 95% CI) otal (random effect, 95% CI)	_	3506	46.5%	9.7%	0.01 [0.01; 0.02] 0.02 [0.01; 0.02]	\
eterogeneity: Tau ² = < 0.0001; Ch	ni ² = 14.24,	df = 6 (I	P = 0.0271); I ²		. <u> </u>	
rug = Gefitinib ouillard,2014	2	107	0.8%	1.6%	0.02 [0.00; 0.07]	
appuzzo,2016 laimaitituersun,2023	2 23	58 122	0.8 % 0.2% 0.1%	1.6% 1.5%	0.02 [0.00; 0.07] 0.03 [0.00; 0.12] 0.19 [0.12; 0.27]	! ——
otal (common effect, 95% CI)		122 287	0.1% 1.2%		0.04 [0.02; 0.06]	\
otal (random effect, 95% Cl) eterogeneity: Tau ² = 0.0076; Chi ²	= 20.27, d	f = 2 (P	< 0.0001); I ² =	4.7% = 90.1%	0.08 [0.00; 0.18]	
rug = Erlotinib	^	00	0.007	4 50/	0.05.10.04 : 0.403	
larkóczy,2018 ark,2015 rugokł 2018	3	62 207	0.2% 2.1%	1.5% 1.7%	0.05 [0.01; 0.13] 0.01 [0.00; 0.04]	
rueckl,2018 otal (common effect, 95% CI)	2	385 654	9.9% 12.1%	1.7%	0.01 [0.00; 0.02] 0.01 [0.00; 0.01]	
otal (random effect, 95% Cl) eterogeneity: Tau ² = < 0.0001; Ch	$ni^2 = 3.35, c$	df = 2 (P	= 0.1870); I ²	4.9% = 40.4%	0.01 [0.00; 0.02]	V :
rug = Befotertinib	-		6 - :		0.4410.00	
u,2022 (50mg) u,2022 (75–100mg)	25 41	176 290	0.2% 0.4%	1.6% 1.6%	0.14 [0.09; 0.20] 0.14 [0.10; 0.19]	
an,2022 (25mg) an,2022 (50mg)	1 13	1 34	0.0% 0.0%	0.1% 0.9%	1.00 [0.03; 1.00] 0.38 [0.22; 0.56]	
an,2022 (75mg) an,2022 (100mg)	2	4	0.0% 0.0%	0.2% 1.0%	0.50 [0.07; 0.93] 0.43 [0.28; 0.59]	
an,2022 (166mg) an,2022 (150mg) otal (common effect, 95% Cl)	2	3 550	0.0% 0.7%	0.2%	0.45 [0.26, 0.35] 0.67 [0.09; 0.99] 0.17 [0.14; 0.20]	•
otal (common effect, 95% Cl) otal (random effect, 95% Cl) eterogeneity: Tau ² = 0.0372; Chi ²				5.7% = 82.9%	0.17 [0.14; 0.20] 0.36 [0.19; 0.53]	
rug = Rezivertinib	– 55. 16, u	1 – 0 (F	< 0.0001),1 =	- 02.970		
hi,2022	22	226	0.4%	1.6%	0.10 [0.06; 0.14]	 :
rug = Oritinib iong,2022	59	286	0.3%	1.6%	0.21 [0.16; 0.26]	
le,2023 otal (common effect, 95% CI)	8	20 306	0.0% 0.3%	0.7%	0.40 [0.19; 0.64] 0.22 [0.17; 0.26]	
otal (random effect, 95% Cl) eterogeneity: Tau ² = 0.0125; Chi ²	- 2 08 df			2.3%	0.27 [0.09; 0.45]	
rug = Nazartinib	– 2.90, ui	- 1 (1 -	0.0041), 1 =	00.570		
an,2020 (75mg)	2	17	0.0%	0.9%	0.12 [0.01; 0.36]	
an,2020 (100mg) an,2020 (150mg)	3 18	38 118	0.1% 0.1%	1.3% 1.5%	0.08 [0.02; 0.21] 0.15 [0.09; 0.23]	
an,2020 (225mg) an,2020 (300mg)	4 5	28 5	0.0% 0.0%	1.1% 0.7%	0.14 [0.04; 0.33] 1.00 [0.48; 1.00]	
otal (common effect, 95% CI) otal (random effect, 95% CI)		206	0.3%	5.6%	0.17 [0.12; 0.21] 0.29 [0.00; 0.62]	•
eterogeneity: Tau ² = 0.1381; Chi ²	= 58.88, d	f = 4 (P	< 0.0001); I ² =		-	
r ug = Furmonertinib ni,2021	34	220	0.3%	1.6%	0.15 [0.11; 0.21]	
rug = Abivertinib		-			_ ,1	: : : : : : : : : : : : : : : : : : :
nou,2022 (50mg) nou,2022 (100mg)	2 4	3 23	0.0% 0.0%	0.2% 1.0%	0.67 [0.09; 0.99] 0.17 [0.05; 0.39]	<u> </u>
nou,2022 (150mg)	5	20	0.0%	0.8%	0.25 [0.09; 0.49]	
nou,2022 (200mg) nou,2022 (250mg)	5 10	20 23	0.0% 0.0%	0.8%	0.25 [0.09; 0.49] 0.43 [0.23; 0.66]	
nou,2022 (300mg) nou,2022 (350mg)	54 2	272 6	0.3% 0.0%	1.6% 0.3%	0.20 [0.15; 0.25] 0.33 [0.04; 0.78]	-
otal (common effect, 95% CI) otal (random effect, 95% CI)		367	0.4%	5.5%	0.22 [0.17; 0.26] 0.25 [0.17; 0.32]	•
eterogeneity: Tau ² = 0.0026; Chi ²	= 8.65, df	= 6 (P =	0.1945); $I^2 = 1$		_ , ,	
r ug = Mobocertinib nou,2021	12	114	0.2%	1.5%	0.11 [0.06; 0.18]	<u> </u>
ida,2021 ida,2021 (160mg) otal (common effect, 95% CI)	1	33 147	0.2 % 0.1% 0.3%	1.5%	0.03 [0.00; 0.16] 0.07 [0.03; 0.11]	<u> </u>
otal (common effect, 95% CI) otal (random effect, 95% CI) eterogeneity: Tau ² = 0.0020; Chi ²			-	3.0% 69.4%	0.07 [0.03; 0.11]	
eterogeneity: Iau ⁻ = 0.0020; Cni ⁻ rug = Almonertinib	– J.∠1, QT	- ı (r =	0.0704), I = 1	JU. T /0		
ang,2020 (55mg)	4	30	0.0%	1.1% 1.6%	0.13 [0.04; 0.31]	
ang,2020 (110mg) ang,2020 (220mg)	18 9	283 39	0.8% 0.0%	1.6% 1.1%	0.06 [0.04; 0.10] 0.23 [0.11; 0.39]	
ang,2020 (260mg) otal (common effect, 95% CI)	3	6 358	0.0% 0.9%	0.3%	0.50 [0.12; 0.88] 0.08 [0.05; 0.10]	•
otal (random effect, 95% Cl) eterogeneity: Tau ² = 0.0080; Chi ²	= 11.16, d	f = 3 (P :	= 0.0109); I ² =	4.2% = 73.1%	0.16 [0.04; 0.27]	
rug = Sunvozertinib						
ang,2022 (400mg)	1	20	0.1%	1.2%	0.05 [0.00; 0.25]	1
ru g = Lazertinib ho,2022 (120mg)	1	25	0.1%	1.4%	0.04 [0.00; 0.20]	'
CT04075396,2021 (240mg) CT04075396,2021 (320mg)	1	15 13	0.0% 0.0%	1.0% 0.9%	0.07 [0.00; 0.32] 0.08 [0.00; 0.36]	· · · · · · · · · · · · · · · · · · ·
otal (common effect, 95% CI) otal (random effect, 95% CI)	ı	53	0.0% 0.1%	0.9% 3.3%	0.05 [0.00; 0.11] 0.05 [0.00; 0.11]	
eterogeneity: Tau ² = 0; Chi ² = 0.2	6, df = 2 (F	P = 0.878	34); $I^2 = 0\%$	J.J /0	5.55 [0.00, 0.11]	1
rug = Zorifertinib		<i>A</i> =	0.007	0.70/	0.27 [0.00: 0.55]	· · · · · · · · · · · · · · · · · · ·
iu,2023 (200mg) iu,2023 (300mg)	4 1	15 15	0.0% 0.0%	0.7% 1.0%	0.27 [0.08; 0.55] 0.07 [0.00; 0.32]	
otal (common effect, 95% CI) otal (random effect, 95% CI)		30	0.0%	1.7%	0.11 [0.00; 0.22] 0.14 [0.00; 0.34]	
eterogeneity: Tau ² = 0.0114; Chi ²	= 2.33, df	= 1 (P =	0.1271); $I^2 = 1$	57%		1 : : : : : : : : : : : : : : : : : : :
rug = Icotinib	1	54	0.3%	1.6%	0.02 [0.00; 0.10]	<u> </u>
v,2023						<u>;</u>
otal (common effect, 95% CI) otal (random effect, 95% CI)		13081	100.0%	100.0%	0.02 [0.02; 0.02] 0.10 [0.08; 0.13]	



